Effect of cytotoxic CD8+ T-cells secretory proteins on hypoxic pancreatic cancer cells. by Eiman Abdo, Mohammad A Ismail, Sabal Al Hadidi, Mairvat Al-Mrahleh, Tareq Saleh, Malik Zihlif, Nidaa A Ababneh

“…In pancreatic cancer, the tumor microenvironment is notably hypoxic and exhibits strong immunosuppressive properties. Given that immunotherapy is now approved for pancreatic cancer treatment, further understanding of how pancreatic tumor cell hypoxia influences T-cell cytotoxicityis essential.…”
Get full text

Reduced irradiation exposure areas enhanced anti-tumor effect by inducing DNA damage and preserving lymphocytes by Huiqin Chen, Yuan Li, Qiaofeng Shen, Guanqun Guo, Zhigang Wang, Hanyu Pan, Min Wu, Xueqing Yan, Gen Yang

“…This approach improved the safety of radiotherapy while maintaining its efficacy in tumor control and provided an opportunity for combining high-dose radiotherapy with immunotherapy.…”
Get full text

The systematic analysis of genes related to butyrate metabolism suggests that CDKN3 could serve as a promising therapeutic target for lung adenocarcinoma treatment by Yanchao Luan, Chao Liang, Qingsong Han, Xueqin Zhou, Na Yang, li Zhao

“…We performed a comprehensive analysis of gene function enrichment between the two populations at risk, thoroughly examined their immune microenvironment characteristics, and assessed the effectiveness of immunotherapy. Finally, the function of CDKN3 in LUAD was verified by in vitro experiments. …”
Get full text

Integrated singlecell and bulk RNA-seq analysis identifies a prognostic signature related to inflammation in colorectal cancer by Wen Yin, Yanting Ao, Qian Jia, Chao Zhang, Liping Yuan, Sha Liu, Wanmeng Xiao, Gang Luo, Xiaomin Shi, Chen Xin, Maolin Chen, Muhan Lü, Zehui Yu

“…Abstract Inflammation can influence the development of CRC as well as immunotherapy and plays a key role in CRC. Therefore, this study aimed to investigate the potential of inflammation-related genes in CRC risk prediction. …”
Get full text

Single-cell sequencing analysis reveals cancer-associated pericyte subgroup in esophageal squamous cell carcinoma to predict prognosis by Kai Xiong, Bing Pan, Hao Fang, Ziyou Tao

“…The drug with a better effect on c5_TYMS was docetaxel (binding energy = -8.1, -8.7 kcal/mol); raloxifene may be more effective against c4_SOD2, although raloxifene has a slightly lower binding energy to SOD2 (-6.4 kcal/mol), it has a higher binding energy to PDGFRβ (-8.1 kcal/mol).ConclusionThe present study identified and discovered pericyte subpopulations that were significantly associated with prognosis, which provides new biomarkers for predicting patient prognosis and adds usable targets for immunotherapy, and it is also important for gaining insights into the composition of the TME in ESCC.…”
Get full text

Feature selection enhances peptide binding predictions for TCR-specific interactions by Hamid Teimouri, Hamid Teimouri, Zahra S. Ghoreyshi, Zahra S. Ghoreyshi, Anatoly B. Kolomeisky, Anatoly B. Kolomeisky, Anatoly B. Kolomeisky, Jason T. George, Jason T. George, Jason T. George, Jason T. George

“…Accurate prediction of peptide binding to TCRs is essential for advancing immunotherapy, vaccine design, and understanding mechanisms of autoimmune disorders.MethodsThis study presents a theoretical approach that explores the impact of feature selection techniques on enhancing the predictive accuracy of peptide binding models tailored for specific TCRs. …”
Get full text

Intracranial germ cell tumors: advancement in genomic diagnostics and the need for novel therapeutics by Kee Kiat Yeo, Kee Kiat Yeo, Joanna Gell, Joanna Gell, Joanna Gell, Girish Dhall, Girish Dhall, Ching Lau, Ching Lau, Ching Lau

“…Other treatment modalities being considered for clinical development include immunotherapy and the use of immune checkpoint inhibitors, especially in NGGCT. …”
Get full text

Immune checkpoint inhibitors in cancer patients with autoimmune disease: Safety and efficacy by Jiayuan Le, Yuming Sun, Guangtong Deng, Yating Dian, Yanli Xie, Furong Zeng

“…The utilization of immune-checkpoint inhibitors (ICIs) in cancer immunotherapy frequently leads to the occurrence of immune-related adverse events (irAEs), making it generally not recommended for patients with preexisting autoimmune diseases. …”
Get full text

Advances in Pure Drug Self-Assembled Nanosystems: A Novel Strategy for Combined Cancer Therapy by Runyan Niu, Xuexue Liu, Xian Yang, Xiao Du, Siliang Wang, Xiaolong Ma, Shaoping Yin, Lihua Shao, Jinping Zhang

“…These include combinations of chemotherapeutic agents, phototherapeutic approaches, the integration of chemotherapy with phototherapy, and the synergistic use of immunotherapy with other treatment methods. Finally, the review highlights the potential of PDANSs in advancing tumor therapy and their prospects for clinical application, providing key insights for future research aimed at optimizing this technology and broadening its utility in cancer treatment.…”
Get full text

Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer by Jorge L. Soriano, Noyde Batista, Eduardo Santiesteban, Mayté Lima, Joaquín González, Robin García, Yohanka Zarza, María V. López, Myriam Rodríguez, Jorge L. Loys, Narciso Montejo, Frank Aguirre, Amparo Macías, Ana M. Vázquez

“…Metronomic chemotherapy combined with 1E10-Alum vaccine immunotherapy might be a useful therapeutic option for the treatment of metastatic breast cancer due to its potential impact on survival and patient quality of live, low toxicity and advantages of the administration.…”
Get full text

Feasibility of individualized home exercise programs for patients with head and neck cancer-study protocol and first results of a multicentre single-arm intervention trial (OSHO #9... by Sabine Felser, Julia Rogahn, Änne Glass, Lars Arne Bonke, Daniel Fabian Strüder, Jana Stolle, Susann Schulze, Markus Blaurock, Ursula Kriesen, Christian Junghanss, Christina Grosse-Thie

“…<h4>Methods and analysis</h4>This prospective, multicentre, single-arm intervention study includes PwHNC ≥18 years of age in aftercare or palliative care with stable remission under immunotherapy. The study opened in January 01, 2021, with estimated completion by December 31, 2024. …”
Get full text

Case report: Watch-and-wait strategy in resectable esophageal cancer following neoadjuvant chemoimmunotherapy: a case series by Lingyu Tan, Lingyu Tan, Guozhen Yang, Guozhen Yang, Chufeng Zeng, Chufeng Zeng, Xu Zhang, Xu Zhang, Xu Zhang

“…On the prerequisite of sufficient tumor regression during neoadjuvant cycles, immunotherapy may facilitate the continued eradication of residual disease in this series.…”
Get full text

EGFR-Mutated Lung Adenocarcinoma With Li–Fraumeni Syndrome: The Imperative for Germline Testing in Patients With a Family History, a Case Report by Hiroyuki Fujii, MD, Yusuke Okuma, MD, PhD, Makoto Hirata, MD, PhD, Yuki Shinno, MD, PhD, Tatsuya Yoshida, MD, PhD, Yasushi Goto, MD, PhD, Hidehito Horinouchi, MD, PhD, Noboru Yamamoto, MD, PhD, Yuichiro Ohe, MD, PhD

“…Remarkably, despite the presence of EGFR mutation, the response to EGFR-tyrosine kinase inhibitor was poor, whereas the response to cytotoxic anticancer drugs and immunotherapy was favorable. After the diagnosis of LFS, she underwent genetic counseling and has been screened for the development of a second cancer based on the Toronto protocol.This case highlights the importance of family history interviews and considering the practice of germline genomic testing for optimal management of lung cancer patients with a hereditary cancer syndrome such as LFS. …”
Get full text

Comprehensive analysis of ESCRT transcriptome-associated signatures and identification of the regulatory role of LMO7-AS1 in osteosarcoma by Shibing Zhao, Dasheng Tian, Fei Huang, Lei Wang, Jinhao Cheng, Zhitao He, Qitian Shen, Shuai Liang, Deliang Gong, Jun Liu, Chengfeng Yi, Chun Zhang, Erbao Bian, Juehua Jing, Tao Wang

“…Moreover, ERG signature score was found to be associated with the response of OS patients to immunotherapy and anticancer drugs. Additionally, we constructed a prognostic signature consisting of 10 ESCRT-related long noncoding RNAs (ERLs) that effectively predicted the prognosis of OS patients. …”
Get full text

Protocol for a multicentre randomised controlled trial examining the effects of temporarily pausing Bruton tyrosine kinase inhibitor therapy to coincide with SARS-CoV-2 vaccination... by Abhishek Abhishek, Jonathan A Cook, Helen M Parry, Anne Francis, Lelia Duley, Vicki S Barber, Paul Moss, Nicholas Peckham

Get full text

Research hotspots and frontiers in the tumor microenvironment of colorectal cancer: a bibliometric study from 2014 to 2024 by Xinran He, Tingyi Xie, Li Shi, Xuyi Kuang, Lei Li, Xingyu Shang, Bo Fu

“…The main components and signaling in TME, CRC immunotherapy, colorectal cancer liver metastasis, and new research techniques are the hot research directions in this domain. …”
Get full text

Identification of signaling networks associated with lactate modulation of macrophages and dendritic cells by Rapeepat Sangsuwan, Bhasirie Thuamsang, Noah Pacifici, Phum Tachachartvanich, Devan Murphy, Abhineet Ram, John Albeck, Jamal S. Lewis

“…The advancement in the understanding of cancer immune evasion has manifested the development of cancer immunotherapeutic approaches such as checkpoint inhibitors and interleukin agonists. Although cancer immunotherapy breakthroughs have demonstrated improved potency for cancer treatment, only a fraction of patients effectively respond to these treatments. …”
Get full text

Single-cell sequencing elucidates the mechanism of NUSAP1 in glioma and its diagnostic and prognostic significance by Meng-Yu Zhao, Zhao-Lei Shen, Hongzhen Dai, Wan-Yan Xu, Li-Na Wang, Yu- Gu, Jie-Hui Zhao, Tian-Hang Yu, Cun-Zhi Wang, Jia-feng Xu, Guan-Jun Chen, Dong-Hui Chen, Wen-Ming Hong, Wen-Ming Hong, Fang Zhang

“…In-depth exploration of NUSAP1’s mechanisms in glioblastoma could enhance our understanding of its response to immunotherapy, suggesting that targeting NUSAP1 may offer therapeutic benefits for glioma patients.…”
Get full text

Advances in Cell and Immune Therapies for Melanoma by Tanase Timis, Sanda Buruiana, Delia Dima, Madalina Nistor, Ximena Maria Muresan, Diana Cenariu, Adrian-Bogdan Tigu, Ciprian Tomuleasa

“…Melanoma is regarded as one of the most inflamed cancers due to its high immune cell presence and strong response to immunotherapy, fueling the need for development of immune-driven innovative treatments. …”
Get full text

Do Self-Expanding Metal Stents as a Bridge to Surgery Benefit All Patients with Obstructive Left-Side Colorectal Cancers? by Jun-rong Zhang, Ping Hou, Tian-ran Liao, Yong Wei, Xian-qiang Chen, Bing-qiang Lin

Get full text